JP2013541005A - ヒアルロン酸を使用した腎損傷の評価のための方法ならびに組成物 - Google Patents

ヒアルロン酸を使用した腎損傷の評価のための方法ならびに組成物 Download PDF

Info

Publication number
JP2013541005A
JP2013541005A JP2013530362A JP2013530362A JP2013541005A JP 2013541005 A JP2013541005 A JP 2013541005A JP 2013530362 A JP2013530362 A JP 2013530362A JP 2013530362 A JP2013530362 A JP 2013530362A JP 2013541005 A JP2013541005 A JP 2013541005A
Authority
JP
Japan
Prior art keywords
subject
threshold
concentration
stage
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013530362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541005A5 (enExample
Inventor
アンダーバーグ，ジョゼフ
グレイ，ジェフ
マクファーソン，ポール
ナカムラ，ケヴィン
カンプ，ジェイムス，パトリック
シンバルトル，カイ
ケルム，ジョン，エー．，ジュニア
Original Assignee
アスチュート メディカル，インコーポレイテッド
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウエルス システム オブ ハイヤー エデュケーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウエルス システム オブ ハイヤー エデュケーション filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2013541005A publication Critical patent/JP2013541005A/ja
Publication of JP2013541005A5 publication Critical patent/JP2013541005A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2013530362A 2010-09-24 2011-09-23 ヒアルロン酸を使用した腎損傷の評価のための方法ならびに組成物 Pending JP2013541005A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38642110P 2010-09-24 2010-09-24
US61/386,421 2010-09-24
PCT/US2011/053015 WO2012040592A1 (en) 2010-09-24 2011-09-23 Methods and compositions for the evaluation of renal injury using hyaluronic acid

Publications (2)

Publication Number Publication Date
JP2013541005A true JP2013541005A (ja) 2013-11-07
JP2013541005A5 JP2013541005A5 (enExample) 2014-11-06

Family

ID=45874188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530362A Pending JP2013541005A (ja) 2010-09-24 2011-09-23 ヒアルロン酸を使用した腎損傷の評価のための方法ならびに組成物

Country Status (13)

Country Link
US (1) US20130252264A1 (enExample)
EP (1) EP2619231B1 (enExample)
JP (1) JP2013541005A (enExample)
KR (1) KR20140051099A (enExample)
CN (2) CN103189394B (enExample)
AU (1) AU2011305197B2 (enExample)
BR (1) BR112013006631A2 (enExample)
CA (1) CA2813011A1 (enExample)
EA (1) EA201390294A1 (enExample)
ES (1) ES2619617T3 (enExample)
MX (1) MX348303B (enExample)
NZ (1) NZ609126A (enExample)
WO (1) WO2012040592A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882767B1 (en) * 2012-08-11 2023-07-12 Astute Medical, Inc. Evaluating renal injury using hyaluronic acid
CN119643878B (zh) * 2024-12-25 2025-07-25 中国人民解放军总医院第一医学中心 一种检测肾脏纤维化相关疾病的生物标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036342A2 (en) * 2008-09-26 2010-04-01 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Urinary biomarkers for predicting long-term dialysis
WO2010091231A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP2004208693A (ja) * 2002-12-17 2004-07-29 Sanyo Chem Ind Ltd 抗ヒアルロン酸抗体、これを含む試薬キット、抗ヒアルロン酸抗体の製造法及びヒアルロン酸の測定法
WO2005114186A1 (ja) * 2004-05-20 2005-12-01 Wako Pure Chemical Industries, Ltd. ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
US20090285761A1 (en) * 2008-04-18 2009-11-19 Pharmacophotonics, Llc D/B/A Fast Diagnostics Renal Function Analysis Method and Apparatus
WO2009146450A2 (en) * 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for monitoring immunosuppressant drug levels, renal function, and hepatic function using small volume samples
US8673574B2 (en) * 2008-08-21 2014-03-18 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
NZ610356A (en) * 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) * 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036342A2 (en) * 2008-09-26 2010-04-01 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Urinary biomarkers for predicting long-term dialysis
WO2010091231A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHENG, XINXIAN ET AL.: "Valuation of measurement of serum hyaluronic acid in patients with early diabetic nephropathy", SHAANXI YIXUE ZAZHI, vol. 30, no. 6, JPN6016005520, 2001, pages 366 - 367, ISSN: 0003255322 *
MELIN JAN ET AL.: "Ischemia-induced renal expression of hyaluronan and CD44 in diabetic rats", NEPHRON EXPERIMENTAL NEPHROLOGY, vol. 103, no. 3, JPN6016005529, 2006, pages 86 - 94, ISSN: 0003255327 *
NAKAMURA HIRONORI ET AL.: "A Multifactorial Effect on the Development of Tubulointerstitial Fibrosis in IgA Nephropathy", SHOWA UNIV J MED SCI, vol. 16, no. 4, JPN6016005524, 2004, pages 301 - 309, ISSN: 0003255325 *
勝呂徹: "血中ヒアルロン酸高値の理由", CLINICIAN, vol. 53, no. 551, JPN6016005523, 2006, pages 704 - 706, ISSN: 0003255324 *
北沢孝三等: "慢性腎炎におけるＣＤ４４，ヒアルロン酸（ＨＡ）,オステオポンチン（ＯＰＮ）の役割", リウマチ, vol. 40, no. 2, JPN6016005525, 2000, pages 536 - 73, ISSN: 0003255326 *
桂善也等: "糖尿病腎症における尿中ヒアルロン酸濃度の検討", 糖尿病, vol. 44, no. 1, JPN6016005522, 2001, pages 167 - 1, ISSN: 0003255323 *
矢内: "ヒアルロン酸", 日本臨牀, vol. 第62巻増刊号11, JPN6015021032, 28 November 2004 (2004-11-28), pages 227 - 229, ISSN: 0003082374 *

Also Published As

Publication number Publication date
BR112013006631A2 (pt) 2017-10-24
NZ609126A (en) 2015-05-29
CN106248921A8 (zh) 2017-07-21
AU2011305197B2 (en) 2015-06-11
EP2619231A4 (en) 2014-04-30
ES2619617T3 (es) 2017-06-26
MX2013003204A (es) 2013-06-05
EP2619231B1 (en) 2016-12-21
WO2012040592A1 (en) 2012-03-29
AU2011305197A1 (en) 2013-05-02
CN106248921A (zh) 2016-12-21
CA2813011A1 (en) 2012-03-29
CN103189394A (zh) 2013-07-03
EP2619231A1 (en) 2013-07-31
CN103189394B (zh) 2016-08-17
EA201390294A1 (ru) 2013-09-30
KR20140051099A (ko) 2014-04-30
US20130252264A1 (en) 2013-09-26
MX348303B (es) 2017-06-06

Similar Documents

Publication Publication Date Title
JP6363154B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6054481B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2017032586A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP5981144B2 (ja) 腎損傷および腎不全の診断および予後診断
JP2012517594A (ja) 腎損傷および腎不全の診断および予後診断のための方法および組成物
JP5827226B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6185035B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016194526A (ja) 腎損傷および腎不全の診断および予後診断のための方法および組成物
JP6403712B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6186400B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2014521088A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2015508181A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20170074868A1 (en) Methods and compositions for the evaluation of renal injury using hyaluronic acid
CN103189394B (zh) 利用透明质酸评价肾损伤的方法和组合物
JP2015524926A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2015513673A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
HK1232598A1 (en) Methods and compositions for the evaluation of renal injury using hyaluronic acid
HK1186198B (en) Methods and compositions for the evaluation of renal injury using hyaluronic acid
HK1186198A (en) Methods and compositions for the evaluation of renal injury using hyaluronic acid
JP2016505860A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170124